Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

REGENXBIO Inc. (RGNX)

27.52   -0.39 (-1.4%) 10-01 09:28
Open: 28.05 Pre. Close: 27.91
High: 28.53 Low: 27.02
Volume: 300,627 Market Cap: 1,067M
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 192 full-time employees. The firm's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The firm develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). The company is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 28.596 - 28.737 28.737 - 28.852
Low: 27.302 - 27.493 27.493 - 27.648
Close: 27.535 - 27.822 27.822 - 28.054

Technical analysis

as of: 2020-09-30 4:45:54 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 33.99     One year: 36.29
Support: Support1: 25.92    Support2: 21.57
Resistance: Resistance1: 29.10    Resistance2: 31.07
Pivot: 28.32
Moving Average: MA(5): 27.56     MA(20): 28.44
MA(100): 34.60     MA(250): 37.75
MACD: MACD(12,26): -0.91     Signal(9): -0.99
Stochastic oscillator: %K(14,3): 38.71     %D(3): 36.63
RSI: RSI(14): 43.03
52-week: High: 54.97  Low: 20.03  Change(%): -26.8
Average Vol(K): 3-Month: 33060  10-Days: 45891

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
RGNX has closed above bottom band by 36.2%. Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 30 Sep 2020
Regenxbio Inc (NASDAQ:RGNX) Expected to Post Quarterly Sales of $24.95 Million - MarketBeat

Wed, 30 Sep 2020
REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) - Herald-Mail Media

Mon, 28 Sep 2020
Research Analysts Set Expectations for Regenxbio Inc's FY2022 Earnings (NASDAQ:RGNX) - MarketBeat

Fri, 25 Sep 2020
REGENXBIO to Participate in Upcoming Investor Conferences - PRNewswire

Thu, 24 Sep 2020
REGENXBIO Inc. (RGNX) is primed for evolution with the beta value of 0.91 - The InvestChronicle

Thu, 24 Sep 2020
Is There a Dimmer Outlook Ahead for REGENXBIO Inc.? - The News Heater

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 37
Shares Float (M) 27
% Held by Insiders 14.83
% Held by Institutions 92.37
Shares Short (K) 4,580
Shares Short P. Month (K) 4,310

Stock Financials

EPS -3.640
EPS Est This Year -2.930
EPS Est Next Year -2.950
Book Value (p.s.) 10.670
Profit Margin -222.24
Operating Margin -256.69
Return on Assets (ttm) -19.9
Return on Equity (ttm) -30.2
Qtrly Rev. Growth 110.2
Gross Profit (p.s.) -2.604
Sales Per Share 1.626
EBITDA (p.s.) -3.960
Qtrly Earnings Growth
Operating Cash Flow (M) -112
Levered Free Cash Flow (M) -98

Stock Valuations

PE Ratio -7.64
PEG Ratio
Price to Book value 2.61
Price to Sales 17.10
Price to Cash Flow -9.29

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.